Accredited Investors’s Organon & Co OGN Stock Holding History

Accredited Investors’s Portfolio OGN Stock Details OGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,813	Closed	-$223K	–	190
2021 Q3	$223K	Buy	+6,813	New	+$218K	0.02%	157

Other funds holding OGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Accredited Investors's OGN Position: Q4 2021 in Review

Accredited Investors sold out of Organon & Co (OGN) in Q4 2021, closing a stake of 6,813 shares — an estimated $223K sold.

Accredited Investors first reported a position in OGN in Q3 2021 and held it in 1 quarter. The position peaked at $223K in Q3 2021. 907 funds tracked by Wall St. Rank hold OGN as of Q4 2021.

Accredited Investors reported no remaining Organon & Co position as of Q4 2021 after selling out during the quarter.
Accredited Investors sold 6,813 Organon & Co shares in Q4 2021, an estimated $223K.
Accredited Investors first reported a position in Organon & Co in Q3 2021 and held it in 1 quarter.
Accredited Investors's Organon & Co position peaked at $223K in Q3 2021.
907 funds tracked by Wall St. Rank held Organon & Co as of Q4 2021.

Based on Accredited Investors's 13F filing for Q4 2021, filed 31 Jan 2022.